The Integrated Care Board (ICB) in Greater Manchester has reaffirmed its decision to reject a proposed data platform, which would utilise Palantir technology. The platform, aimed at improving data sharing and analysis across the NHS, has been met with opposition from various quarters, including public concerns and a lack of evidence supporting its benefits.
The ICB stated that public concern has only grown since the initial proposal, and despite efforts to address these concerns, the decision to reject the platform remains unchanged. The organisation has also cited the lack of evidence supporting the platform's benefits as a key reason for the rejection.
Palantir's technology has been utilised in various sectors, including defence and finance, but its use in the NHS has been met with controversy. The platform's proposed use in Greater Manchester has raised concerns about the potential risks to patient data and the impact on local healthcare services.
The rejection of the platform has implications for the UK's NHS data sharing and analysis, particularly in the context of the UK ICO's guidance on data protection. The EU AI Act, currently in development, may also impact the way Palantir's technology is utilised in the UK.
Commenting on the decision, an expert in healthcare technology noted that while the rejection of the platform may be disappointing for some, it highlights the importance of transparency and public engagement in the development of healthcare technology. 'The NHS must prioritise the needs and concerns of patients and healthcare staff when implementing new technology,' the expert said.